Literature DB >> 3015978

Pattern of fibronectin distribution in human lung cancer.

H Nagai, M Isemura, H Arai, T Abe, S Shimoda, M Motomiya, H Sato, K Hashimoto, K Takusagawa, K Konno.   

Abstract

The pattern of fibronectin (FN) distribution in human lung cancer was studied by indirect immunofluorescent staining, and by the peroxidase-antiperoxidase method in a total of 60 surgical specimens. They comprised 8 small cell carcinomas, 4 large cell carcinomas, 19 squamous cell carcinomas, 28 adenocarcinomas, and 1 adenoid cystic carcinoma. Of the 60 specimens 13 were FN-positive. They included 4 large cell carcinomas, 4 small cell carcinomas, 3 poorly differentiated squamous cell carcinomas, and 2 poorly differentiated and 1 moderately differentiated adenocarcinomas. On the other hand, none of the well differentiated carcinomas was FN-positive around tumor cells. Our data suggest that undifferentiated, or poorly differentiated carcinomas of the lung tend to be FN-positive.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015978     DOI: 10.1007/bf00394930

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  13 in total

1.  The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes.

Authors:  L A Sternberger; P H Hardy; J J Cuculis; H G Meyer
Journal:  J Histochem Cytochem       Date:  1970-05       Impact factor: 2.479

2.  Changes in the distribution of fibronectin in the placenta during normal human pregnancy.

Authors:  Y Yamaguchi; M Isemura; Z Yosizawa; K Kurosawa; K Yoshinaga; A Sato; M Suzuki
Journal:  Am J Obstet Gynecol       Date:  1985-07-15       Impact factor: 8.661

3.  Fibronectin: purification, immunochemical properties, and biological activities.

Authors:  E Ruoslahti; E G Hayman; M Pierschbacher; E Engvall
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

4.  The early appearance of fibronectin in the course of metastatic tumor growth in lymph nodes.

Authors:  D Lorke; P Möller
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  Serum levels of fibronectin and a fibronectin-like DNA-binding protein in patients with various diseases.

Authors:  H D Todd; M S Coffee; T P Waalkes; M D Abeloff; R G Parsons
Journal:  J Natl Cancer Inst       Date:  1980-11       Impact factor: 13.506

6.  Loss of fibronectin in human breast cancer.

Authors:  J Labat-Robert; P Birembaut; J J Adnet; F Mercantini; L Robert
Journal:  Cell Biol Int Rep       Date:  1980-06

7.  Possible role of fibronectin in malignancy.

Authors:  L B Chen; I Summerhayes; P Hsieh; P H Gallimore
Journal:  J Supramol Struct       Date:  1979

8.  Correlation between tumor induction and the large external transformation sensitive protein on the cell surface.

Authors:  L B Chen; P H Gallimore; J K McDougall
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

9.  Distribution of fibronectin in fibrotic human livers at various states.

Authors:  N Kojima; M Isemura; Z Yosizawa; T Ono; S Shinada; K Soga; Y Aoyagi; F Ichida
Journal:  Tohoku J Exp Med       Date:  1981-12       Impact factor: 1.848

10.  Ultrastructural localization of fibronectin in duct cells of human minor salivary glands and its immunochemical detection in minor salivary gland secretion.

Authors:  A Linde; L E Berghem; H A Hansson; R Jonsson; Y Redfors
Journal:  Arch Oral Biol       Date:  1984       Impact factor: 2.633

View more
  2 in total

1.  The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells.

Authors:  Christina Cho; Carol Horzempa; David Jones; Paula J McKeown-Longo
Journal:  BMC Cancer       Date:  2016-08-02       Impact factor: 4.430

Review 2.  Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology.

Authors:  Francesca Di Modugno; Paola Nisticò; Sheila Spada; Annalisa Tocci
Journal:  J Exp Clin Cancer Res       Date:  2021-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.